EA201891851A1 - Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений - Google Patents

Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений

Info

Publication number
EA201891851A1
EA201891851A1 EA201891851A EA201891851A EA201891851A1 EA 201891851 A1 EA201891851 A1 EA 201891851A1 EA 201891851 A EA201891851 A EA 201891851A EA 201891851 A EA201891851 A EA 201891851A EA 201891851 A1 EA201891851 A1 EA 201891851A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
application
immunological disorders
antibodies against
malignant neoplasms
Prior art date
Application number
EA201891851A
Other languages
English (en)
Inventor
Джанго Сассман
Морин РАЙАН
Лори Вестендорф
Майкл Фельдхаус
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2017/018177 external-priority patent/WO2017143069A1/en
Publication of EA201891851A1 publication Critical patent/EA201891851A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение обеспечивает гуманизированные антитела, которые специфически связываются с BCMA. Указанные антитела полезны для лечения и диагностики различных видов злокачественных новообразований и иммунологических нарушений, а также для выявления BCMA.
EA201891851A 2016-09-16 2017-02-16 Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений EA201891851A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662396084P 2016-09-16 2016-09-16
PCT/US2017/018177 WO2017143069A1 (en) 2016-02-17 2017-02-16 Bcma antibodies and use of same to treat cancer and immunological disorders

Publications (1)

Publication Number Publication Date
EA201891851A1 true EA201891851A1 (ru) 2019-04-30

Family

ID=62639290

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891851A EA201891851A1 (ru) 2016-09-16 2017-02-16 Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений

Country Status (2)

Country Link
EA (1) EA201891851A1 (ru)
TW (2) TW202344518A (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078688A2 (en) * 2010-12-06 2012-06-14 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
WO2015166073A1 (en) * 2014-04-30 2015-11-05 Max-Delbrück-Centrum für Molekulare Medizin Humanized antibodies against cd269 (bcma)

Also Published As

Publication number Publication date
TW202344518A (zh) 2023-11-16
TWI793075B (zh) 2023-02-21
TW201813980A (zh) 2018-04-16

Similar Documents

Publication Publication Date Title
MX2018009700A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
EA201892294A1 (ru) Антитела и композиции против tim-3
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201891909A1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201790413A1 (ru) Антитела против tigit
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201691541A1 (ru) Новые анти-baff антитела
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201892716A1 (ru) Антитела к фактору свертывания xi